Fact Meets Function

Self-Cross-Linked Hydrogel of Cysteamine-Grafted γ-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats.

This animal model study evaluated a self-cross-linked hydrogel delivery system combining cysteamine-grafted γ-polyglutamic acid with the tripeptide KPV in rats with TNBS-induced ulcerative colitis. The hydrogel formulation demonstrated improved stability of the KPV tripeptide and showed alleviating effects on colitis markers in the rat model. This represents preclinical research requiring further development before clinical translation.

Self-Cross-Linked Hydrogel of Cysteamine-Grafted γ-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats. Read Post »

Treatment of Kleine-Levin Syndrome With Intranasal Photobiomodulation and Methylene Blue.

This human clinical study describes the treatment of Kleine-Levin Syndrome (a rare condition characterized by recurrent episodes of hypersomnia and behavioral changes) using intranasal photobiomodulation combined with methylene blue in individual patient cases. The report documents patient responses to this combined intervention approach, though specific efficacy data and outcome measures are not detailed in the provided information. As a human clinical case report or small series, this represents lower-level evidence compared to randomized controlled trials.

Treatment of Kleine-Levin Syndrome With Intranasal Photobiomodulation and Methylene Blue. Read Post »

Methylene blue and photobiomodulation recover cognitive impairment in hepatic encephalopathy through different effects on cytochrome c-oxidase.

Researchers investigated how methylene blue and photobiomodulation (light therapy) each improved cognitive function in an animal model of hepatic encephalopathy by examining their effects on cytochrome c-oxidase, a key enzyme in cellular energy production. Both treatments restored cognitive performance in affected animals, but through distinct mechanisms—methylene blue directly enhanced cytochrome c-oxidase activity while photobiomodulation worked through different pathways affecting the same enzyme. This animal model study provides mechanistic insight into how these interventions may address the mitochondrial dysfunction underlying cognitive impairment in hepatic encephalopathy.

Methylene blue and photobiomodulation recover cognitive impairment in hepatic encephalopathy through different effects on cytochrome c-oxidase. Read Post »

Methylene blue reduces incidence of early postoperative cognitive disorders in elderly patients undergoing major non-cardiac surgery: An open-label randomized controlled clinical trial.

This open-label randomized controlled clinical trial (human clinical evidence) investigated whether methylene blue could reduce early postoperative cognitive dysfunction (POCD) in elderly patients undergoing major non-cardiac surgery. The study found that methylene blue treatment reduced the incidence of early POCD in this patient population compared to control. This represents direct clinical evidence from a human trial, though the open-label design (where participants and researchers knew treatment assignment) represents a moderate strength of evidence compared to blinded trials.

Methylene blue reduces incidence of early postoperative cognitive disorders in elderly patients undergoing major non-cardiac surgery: An open-label randomized controlled clinical trial. Read Post »

Tripeptide/Hexapeptide Topical in Esthetics: Evidence behind the Skincare Formulation.

This review article examined the evidence supporting the use of tripeptide and hexapeptide formulations, particularly GHK-Cu, in topical skincare products for esthetic applications (evidence level: review of clinical and in vitro studies). The review synthesized existing research on how these peptides function in skin formulations, including their purported mechanisms related to collagen production and skin appearance. The article provides an overview of the scientific basis behind peptide-containing skincare products used in esthetic practice.

Tripeptide/Hexapeptide Topical in Esthetics: Evidence behind the Skincare Formulation. Read Post »

Hydrogels based on low-methoxyl amidated citrus pectin and flaxseed gum formulated with tripeptide glycyl-l-histidyl-l-lysine improve the healing of experimental cutting wounds in rats.

Researchers evaluated hydrogels made from low-methoxyl amidated citrus pectin and flaxseed gum combined with the tripeptide GHK (glycyl-L-histidyl-L-lysine) for wound healing in a rat cutting wound model. The hydrogel formulation demonstrated improved healing outcomes in the experimental wounds compared to control groups. This is **animal model evidence** with no direct human clinical applicability at this stage.

Hydrogels based on low-methoxyl amidated citrus pectin and flaxseed gum formulated with tripeptide glycyl-l-histidyl-l-lysine improve the healing of experimental cutting wounds in rats. Read Post »

NAD+ therapy in age-related degenerative disorders: A benefit/risk analysis.

This review article examined the potential benefits and risks of NAD+ (nicotinamide adenine dinucleotide) therapeutic approaches, including NMN supplementation, across age-related degenerative diseases by analyzing existing clinical and preclinical evidence. The authors assessed both the rationale for NAD+ augmentation in aging-related conditions and identified potential safety concerns requiring consideration in therapeutic development. This is a **review article** synthesizing existing human clinical, animal model, and in vitro research rather than original research data.

NAD+ therapy in age-related degenerative disorders: A benefit/risk analysis. Read Post »

An evaluation of hydromethylthionine as a treatment option for Alzheimer’s disease.

This human clinical study evaluated hydromethylthionine (a formulation of methylene blue) as a potential therapeutic agent for Alzheimer’s disease, examining its pharmacological properties and clinical efficacy based on available evidence. The research assessed hydromethylthionine’s mechanism of action, safety profile, and effectiveness in slowing cognitive decline in Alzheimer’s patients, contributing to the expert analysis of its role among treatment options. This evidence represents human clinical research on a pharmaceutical intervention for neurodegenerative disease.

An evaluation of hydromethylthionine as a treatment option for Alzheimer’s disease. Read Post »

Scroll to Top